Survival and Clinical Trial Design
Tarceva (erlotinib) in combination with gemcitabine is indicated for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Here you can find details concerning recently completed trial for Pancreatic Cancer. You can also read about survival and other efficacy results.
Clinical Trial Design
Examine the Tarceva trials design and study population.
Survival Results
Review the results of trials for pancreatic cancer and find more information about Tarceva clinical trial efficacy.

